Taylor Nordan1, Ann M Thomas2, Elizabeth S Ginsburg2, Patrick Y Wen2, Andrey V Dolinko3, Pietro Bortoletto2. 1. Department of Obstetrics, Gynecology, and Reproductive Biology, Center for Infertility and Reproductive Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. taylornordan125@gmail.com. 2. Department of Obstetrics, Gynecology, and Reproductive Biology, Center for Infertility and Reproductive Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. 3. Department of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, 101 Dudley Street, Providence, RI, 02905, USA.
Abstract
PURPOSE: With advances in cancer therapy, reproductive-aged women can look forward to a life post-malignancy. Fortunately, fertility preservation (FP) may provide relief from potential infertility caused by cancer or associated caustic treatments. Outcomes of FP in pre-treatment reproductive-aged women with gliomas have not been previously characterized. METHODS: Between 2007 and 2018, 10 patients undergoing FP prior to chemotherapy and/or radiation treatment for gliomas were identified at Brigham and Women's Hospital. They were matched 3:1 to male-factor infertility patients by age ± 1 year. RESULTS: Patients with gliomas had significantly lower baseline anti-Müllerian hormone levels than male-factor infertility controls (2.37 vs 5.16 ng/mL, p = 0.002, log transformed). Despite higher starting (350 vs. 240 IU, p = 0.004) and total gonadotropin doses (4270 vs. 2270 IU, p < 0.001) over a similar stimulation duration (12.1 vs. 11.1 days, p = 0.219), cancer patients had lower peak estradiol levels (1420 vs. 2245 pg/mL, p = 0.003). The total number of follicles on the day of trigger (14.1 vs. 15.6, p = 0.284), the number of oocytes retrieved (18.4 vs. 20.5, p = 0.618), and the percentage of mature oocytes (69.9 vs. 73.8%, p = 0.076) were similar between cases and controls. One patient returned for a cryopreserved embryo transfer and delivered a healthy child. CONCLUSIONS: Patients undergoing FP prior to chemotherapy and/or radiation for a glioma achieve satisfactory FP outcomes and should be appropriately counseled regarding the opportunity to family-build after treatment.
PURPOSE: With advances in cancer therapy, reproductive-aged women can look forward to a life post-malignancy. Fortunately, fertility preservation (FP) may provide relief from potential infertility caused by cancer or associated caustic treatments. Outcomes of FP in pre-treatment reproductive-aged women with gliomas have not been previously characterized. METHODS: Between 2007 and 2018, 10 patients undergoing FP prior to chemotherapy and/or radiation treatment for gliomas were identified at Brigham and Women's Hospital. They were matched 3:1 to male-factor infertilitypatients by age ± 1 year. RESULTS:Patients with gliomas had significantly lower baseline anti-Müllerian hormone levels than male-factor infertility controls (2.37 vs 5.16 ng/mL, p = 0.002, log transformed). Despite higher starting (350 vs. 240 IU, p = 0.004) and total gonadotropin doses (4270 vs. 2270 IU, p < 0.001) over a similar stimulation duration (12.1 vs. 11.1 days, p = 0.219), cancerpatients had lower peak estradiol levels (1420 vs. 2245 pg/mL, p = 0.003). The total number of follicles on the day of trigger (14.1 vs. 15.6, p = 0.284), the number of oocytes retrieved (18.4 vs. 20.5, p = 0.618), and the percentage of mature oocytes (69.9 vs. 73.8%, p = 0.076) were similar between cases and controls. One patient returned for a cryopreserved embryo transfer and delivered a healthy child. CONCLUSIONS:Patients undergoing FP prior to chemotherapy and/or radiation for a glioma achieve satisfactory FP outcomes and should be appropriately counseled regarding the opportunity to family-build after treatment.
Entities:
Keywords:
Fertility preservation; Glioma; In vitro fertilization
Authors: Quinn T Ostrom; Haley Gittleman; Peter M de Blank; Jonathan L Finlay; James G Gurney; Roberta McKean-Cowdin; Duncan S Stearns; Johannes E Wolff; Max Liu; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2016-01 Impact factor: 12.300
Authors: Alexander R Mehm; David P Steensma; Serene S Srouji; Elizabeth S Ginsburg; Paula C Brady Journal: Am J Hematol Date: 2018-05-13 Impact factor: 10.047
Authors: Kate E Waimey; Brigid M Smith; Rafael Confino; Jacqueline S Jeruss; Mary Ellen Pavone Journal: J Womens Health (Larchmt) Date: 2015-06-15 Impact factor: 2.681
Authors: Rachel K Stiner; Jennifer L Clarke; Nikita Sinha; Jessica Chan; Joseph M Letourneau; Erin E Niemasik; Jane E Rabbitt; Susan M Chang; Nicholas A Butowski; Michael D Prados; Mitchell P Rosen Journal: Neurooncol Pract Date: 2018-09-26